Results 211 to 220 of about 65,941 (263)
Some of the next articles are maybe not open access.
Circulation, 1997
Background The mechanisms by which ACE inhibitors produce a sustained clinical benefit are not entirely clear but may involve the sympathetic nervous system. We compared the effect of local brachial artery infusions of an ACE inhibitor (perindoprilat) with the effect of placebo (0.9% NaCl) on endogenously mediated (lower body ...
D, Lyons, S, Roy, S, O'Byrne, C G, Swift
openaire +2 more sources
Background The mechanisms by which ACE inhibitors produce a sustained clinical benefit are not entirely clear but may involve the sympathetic nervous system. We compared the effect of local brachial artery infusions of an ACE inhibitor (perindoprilat) with the effect of placebo (0.9% NaCl) on endogenously mediated (lower body ...
D, Lyons, S, Roy, S, O'Byrne, C G, Swift
openaire +2 more sources
Vascular Effects of ACE Inhibition by Perindopril
Drugs, 1990Hypertension and ageing are associated with decreased arterial compliance, increased thickening of the arterial wall, hypertrophy of arterial smooth muscle cells and an increase in the collagen content of the arterial wall. Increased blood pressure has been implicated as a causative factor in such adaptive vascular alterations, however, other factors ...
J B, Michel, B I, Levy
openaire +2 more sources
ACE Inhibition in Diabetic Patients
PharmacoEconomics, 1996Diabetic nephropathy is the inevitable long term complication of prolonged hyperglycaemia for up to 40% of patients with diabetes mellitus. Most patients with renal involvement have a number of comorbid conditions including hypertension, coronary artery disease. peripheral vascular disease and retinopathy.
R A, Rodby, E J, Lewis
openaire +2 more sources
Evidence-Based Medicine and ACE Inhibition
Journal of Cardiovascular Pharmacology, 1998The use of angiotensin-converting enzyme (ACE) inhibitors has been generally beneficial in the treatment of many clinical conditions characterized by a significant degree of cardiovascular and renal involvement. Most of the available data on the benefits of ACE inhibitors have come from well-conducted large clinical trials that have provided much ...
C, Borghi, E, Ambrosioni
openaire +2 more sources
ACE Inhibition and the Vascular Intima in Hypertension
Journal of Cardiovascular Pharmacology, 1993Both the function and the morphology of the vascular intima are altered during hypertension. In spontaneously hypertensive rats, endothelium-dependent relaxation is decreased, and the subendothelium becomes infiltrated with monocyte macrophages. It is not known if these two features are secondary to high blood pressure and what their consequences are ...
M, Clozel, H, Kuhn, H R, Baumgartner
openaire +2 more sources
Journal of Cardiovascular Pharmacology, 1990
Results of uncontrolled studies suggest that the duration of action of an ACE inhibitor may be an important determinant of renal impairment when using these agents to treat patients with heart failure. To determine whether there is experimental evidence for this hypothesis, we compared the effects of intermittent (captopril, 25 mg i.v.
M A, Fitzpatrick +6 more
openaire +2 more sources
Results of uncontrolled studies suggest that the duration of action of an ACE inhibitor may be an important determinant of renal impairment when using these agents to treat patients with heart failure. To determine whether there is experimental evidence for this hypothesis, we compared the effects of intermittent (captopril, 25 mg i.v.
M A, Fitzpatrick +6 more
openaire +2 more sources
ACE Inhibition in Hypertension
American Journal of Cardiovascular Drugs, 2007Ongoing developments in our understanding of cardiovascular disease, together with the introduction of new drugs to treat these conditions, has led to much debate over the optimal management of hypertension. The ALLHAT study showed no major differences in cardiovascular outcome among three major classes of antihypertensive drugs.
openaire +2 more sources
The Effects of ACE Inhibition on Progression of Atherosclerosis
Journal of Cardiovascular Pharmacology, 1993Angiotensin-converting enzyme inhibitors have been extensively studied and established in the treatment of hypertension, heart failure, and ventricular dysfunction. They have various cardiac and vascular protective effects, but the relevant mechanisms of action in these areas remain to be fully understood.
openaire +2 more sources
ACE inhibition in the tissues.
Clinical physiology and biochemistry, 1993The discovery of the components of the renin angiotensin system (RAS) in various tissues gave rise to the idea that functional "tissue" renin-angiotensin systems exist that are more or less independent of the hormonal RAS. Further support to this notion came from the recent demonstration of the mRNA for the protein components of the RAS in a number of ...
T, Unger, P, Gohlke
openaire +1 more source
Triple ACE-ECE-NEP Inhibition in Heart Failure: A Comparison With ACE and Dual ECE-NEP Inhibition
Journal of Cardiovascular Pharmacology, 2005Abstract: Mortality remains high in chronic heart failure (CHF) because under ACE inhibitor treatment other neurohumoral systems remain/become (de)activated, such as the endothelin and atrial natriuretic peptide pathways.
Virginie, Mellin +6 more
openaire +2 more sources